510(k) · Radiology

ART-Plan

by Therapanacea SAS

ART-Plan is an AI-enabled medical device from Therapanacea SAS that the U.S. FDA cleared through 510(k) K230023 on April 19, 2023. Its lead review panel is Radiology and its primary product code is QKB (Radiological Image Processing Software For Radiation Therapy).

See also FDA-cleared AI radiology devices in 2023, all FDA AI clearances in 2023, top radiology AI devices.

Key facts

Submission numberK230023
Pathway510(k)
Date of final decision
Company (FDA list)Therapanacea SAS
Lead review panelRadiology
Primary product codeQKB — Radiological Image Processing Software For Radiation Therapy
Applicant (openFDA)Therapanacea Sas
Applicant locationParis, FR
Device classClass 2
Regulation number21 CFR 892.2050
Decision codeSESE
Submission typeSpecial

Source: FDA AI-Enabled Medical Devices list and openFDA.

What this means

A 510(k) is a premarket submission showing the device is substantially equivalent to a legally marketed predicate device. A cleared 510(k) means FDA agreed with that equivalence. ART-Plan went through this pathway (K230023).

openFDA lists it as a Class 2 device under 21 CFR 892.2050. Class II devices are moderate risk and are subject to general and special controls.

Product code QKB covers 46 devices on the FDA AI list. By decision date, this device is #25 of 46 under that code. Therapanacea SAS has 4 AI-enabled devices on the list, and the Radiology panel accounts for 1,230 in total.

Being on this list doesn't describe how well the device works clinically. Check the FDA record for its indications for use.

Similar devices (product code QKB)

More from Therapanacea SAS